… In this post hoc analysis of the DAPA-CKD trial, we assessed the effects of dapagliflozin on
first hospitalizations and all (first and subsequent) hospitalizations in patients with CKD with …

… In this prespecified exploratory analysis of pooled data from two complementary phase 3
studies, the DAPA-CKD and DAPA-HF trials, our findings suggest that dapagliflozin appears to …

… In this prespecified subgroup analysis of the DAPA-CKD trial, we show beneficial effects
of dapagliflozin on kidney and cardiovascular end points in patients with stage 4 CKD at …

… was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, … trial
results according to history of HF. We calculated HRs (95% CIs) for the effect of dapagliflozin …

… the DAPA-CKD trial, we found that the benefit of dapagliflozin … with type 2 diabetes and CKD
was consistent across all classes … We also found that dapagliflozin reduced the initiation of …

… effects of dapagliflozin on the prespecified kidney and cardiovascular outcomes in patients
with chronic kidney disease … disease, in the DAPA-CKD trial (Dapagliflozin and Prevention of …

… from a very well characterized study population. The DAPA-CKD data thus extend our
knowledge on the causes of death in patients with advanced CKD in that non-cardiovascular …

… As previously reported, the DAPA-CKD study included 115 participants with a diagnosis of
FSGS [21]. In this prespecified analysis, we investigated the effects of dapagliflozin in patients …

… amplified in the presence of CKD and increased albuminuria. In this analysis from the
DAPA-CKD trial, we demonstrated that dapagliflozin, compared with placebo, was associated with …

… -level data from the DAPA-CKD trial, we estimate that long-term treatment with dapagliflozin
may … Notably, we estimated delayed CKD progression through treatment with dapagliflozin to …